April Deal Volume Was Decent

by | Apr 29, 2016 6:51 pm | Biotechnology, eHealth, Long-Term Care | 0 comments

We’re still in preliminary territory, so don’t bank on this yet. Health care M&A hit 120 deals for the month of April 2016, down 12% versus the previous month’s 136 deals, but 7% better than the same month a year ago. Long-term care deals led the transaction activity with 21 deals (18% of the total), with Biotechnology (17 deals, 14%) and eHealth (16 deals, 13%) close behind. Thanks to the $30.7 billion Abbott (NYSE: ABT) offer for St. Jude Medical (NYSE: SJM), spending for the month was far higher than in recent months. April’s deal value now stands at $42.2 billion, up 240% compared with March’s $12.4 billion and 732% compared with April 2015’s... Read More »

AbbVie Buys a Pipeline

by | Apr 29, 2016 6:37 pm | Biotechnology, Pharmaceuticals | 0 comments

After only four deals announced in 2014 and 2015, AbbVie (NYSE: ABBV) gained momentum in the M&A space this year in an effort to expand and diversify its portfolio. The timing isn’t a coincidence, since it faces the looming expiration of Humira’s patent in December. The drug that accounted for 63% of AbbVie’s 2014 sales could lose its dominant position in the autoimmune disease market as competitive generics take the field. In the first four months of 2016, AbbVie has dished out $6.4 billion on three deals (two collaborations and one acquisition). On March 7th, the company announced a collaboration with Boehringer Ingelheim that added anti-IL-23 to its immunology pipeline. The... Read More »

Abbott’s $30.7B Deal Boosts Medical Device M&A

by | Apr 28, 2016 8:46 pm | Laboratories, MRI & Dialysis, Medical Devices, Pharmaceuticals | 0 comments

Medical device deals are back in fashion. In the first four months of 2016, 41 deals were announced in this sector, compared with just 30 for the comparable time period in 2015. Spending on deals in this sector has already hit $42.7 billion, compared with $5.7 billion in the first four months of 2015. The largest by far this year is Abbott’s (NYSE: ABT) announcement on April 28 that it would spend $30.7 billion to acquire Minneapolis-based St. Jude Medical, Inc. (NYSE: SJM). St. Jude shareholders will receive $46.75 in cash and 0.8708 shares of Abbott common stock, representing total consideration of approximately $85 per share, and a transaction equity value of $25 billion. Add in... Read More »

Veritas Capital Buys Back into Big Data

by | Apr 26, 2016 5:55 pm | eHealth, Private Equity | 0 comments

Big data firms are sweet targets for healthcare investors. Just last February, Veritas Capital sold Truven Health Analytics to IBM Watson Health (NYSE: IBM) for $2.6 billion. Now it’s putting some of that ROI into another big data firm, Verisk Health, the healthcare service business Verisk Analytics Inc. Verisk Health provides data services, analytics and advanced technologies to help users make smarter business decisions and reduce risk. The $820 million purchase price consists of $720 million in cash and a $100 million long-term subordinated promissory note. With Truven Health Analytics, Veritas Capital repositioned the company from a data provider with limited analytics offerings... Read More »